Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 31490921.
- Also identified by DOI 10.1371/journal.pmed.1002915 and PMC identifier 6730844.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Christian Lienhardt and colleagues discuss the importance of communication and coordination between regulators, researchers, and policy makers to ensure tuberculosis trials provide high-quality evidence for policy decisions.
Medical subject headings
- Antitubercular Agents
- Clinical Trials as Topic
- Drug Approval
- Endpoint Determination
- Public Health
- Research Design
- Tuberculosis